menu

Cardiovascular Disease & Comorbidities in SpA

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiovascular Disease & Comorbidities in SpA

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Find out how increased cardiovascular risk could impact patients with SpA—and how we can better manage this risk.

  • Sponsored by

  • Overview

    Patients with spondyloarthritis, or SpA for short, can be at an increased cardiovascular risk.1,2 To learn how we can better understand and manage this risk, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

    Dr. Dua and Dr. Husni are Novartis consultants.

    1. Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatol (United Kingdom). 2020;59:iv47-iv57.
    2. Papagoras C, Markatseli TE, Saougou I, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2014;81(1):57-63.

    196466     6/22

Schedule12 Aug 2022
Webpack App